Our finding that TRPV2-mediated phagocytosis is impaired in smoke-exposure mice suggests that TRPV2 agonists may have potential to ameliorate cigarette-induced COPD in humans. Here, TRPV2 is linked to chronic obstructive pulmonary disease.